Literature DB >> 34950309

Routine Transesophageal Echocardiography in Atrial Fibrillation Before Electrical Cardioversion to Detect Left Atrial Thrombosis and Echocontrast.

Sebastian Feickert1,2, Giuseppe D Ancona2,1, Hüseyin Ince2, Kristof Graf3, Elias Kugel3, Monica Murero2,4, Erdal Safak2.   

Abstract

BACKGROUND: Transesophageal echocardiography (TEE) before electrical cardioversion (ECV) in atrial fibrillation (AF) is not routinely performed in anticoagulated patients.
METHODS: Starting from TEE findings of anticoagulated and non-anticoagulated patients referred for ECV, we investigated the rate of spontaneous echo-contrast (SEC) and left atrial thrombus (LAT) and identified their independent predictors.
RESULTS: A total of 403 patients were included: 262 (65%) had no anticoagulation, 47 (11.7%) were onnovel oral anticoagulant (rivaroxaban), 74 (18.4%) on warfarin INR>2, and 20 (5.0%) on warfarin INR<2.In 41 (10.1%) there was LAT and in 154 (38.2%) SEC. Patients with LAT had a significantly lower left ventricular ejection fraction (LVEF%) (p=0.001). Patients with SEC were significantly older (p=0.04), had lower LVEF% (p<0.0001),higher CHADSVASC score (p<0.0001), and higher rate of coronary artery disease (CAD) (p=0.03). In 56.8% of warfarin patients (INR>2) there was SEC (p=0.002). At multivariate analysis therapeutic anticoagulation with warfarin (p=0.003; OR:2.2; CI: 1.3-3.7),CHADSVASC score (p<0.0001; OR=1.2; CI: 1.1-1.4), and LVEF% (p<0.0001; OR:0.95; CI: 0.93-0.97; inverse relationship) were SEC predictors. A 3.5 CHADSVASC score cut-off was predictor of SEC (AUC: 0.7; p<0.0001). LVEF% was the only predictor of LAT (p=0.02; OR=0.96; CI: 0.93-0.99; inverse relationship).
CONCLUSIONS: Echocardiography before ECV identifies clear LAT/SEC in more than a third of AF patients, independently by their anticoagulation regimen. LAT/SEC rates increasewith decrement of LVEF%. Increment of CHADSVASC score increases SEC risk. In anticoagulated patients SEC rate remains higher than expected. Therapeutic anticoagulation with Warfarin appears positively and independently correlated to SEC occurrence.

Entities:  

Keywords:  Atrial; Echocardiography; Echocontrast; Fibrillation; Thrombus; Transesophageal

Year:  2020        PMID: 34950309      PMCID: PMC8691341          DOI: 10.4022/jafib.2364

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  24 in total

1.  Influence of warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation.

Authors:  T Ito; M Suwa; T Nakamura; S Miyazaki; Y Hirota; K Kawamura
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

2.  Usefulness of transesophageal echocardiography before cardioversion in atrial arrhythmias.

Authors:  Katarzyna Kosmalska; Małgorzata Rzyman; Paweł Miękus; Natasza Gilis-Malinowska; Radosław Nowak; Marcin Fijałkowski
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

3.  Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation : Systematic analysis of a single-center experience.

Authors:  A G Bejinariu; D U Härtel; J Brockmeier; R Oeckinghaus; A Herzer; U Tebbe
Journal:  Herz       Date:  2016-04-21       Impact factor: 1.443

4.  NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world.

Authors:  Emanuele Bertaglia; Matteo Anselmino; Alessandro Zorzi; Vincenzo Russo; Elisabetta Toso; Francesco Peruzza; Antonio Rapacciuolo; Federico Migliore; Fiorenzo Gaita; Umberto Cucchini; Marcello De Divitiis; Sabino Iliceto; Giuseppe Stabile
Journal:  Int J Cardiol       Date:  2017-12-15       Impact factor: 4.164

5.  Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: a single centre 8.5-year experience.

Authors:  G Corrado; M Santarone; S Beretta; G Tadeo; L M Tagliagambe; G Foglia-Manzillo; M Spata; E Miglierina; F Acquati; M Santarone
Journal:  Europace       Date:  2000-04       Impact factor: 5.214

6.  Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.

Authors:  Maura M Zylla; Mara Pohlmeier; Alexander Hess; Derliz Mereles; Meinhard Kieser; Thomas Bruckner; Eberhard Scholz; Edgar Zitron; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Am J Cardiol       Date:  2014-12-18       Impact factor: 2.778

Review 7.  Is early cardioversion for atrial fibrillation safe in patients with spontaneous echocardiographic contrast?

Authors:  S V Patel; Greg Flaker
Journal:  Clin Cardiol       Date:  2008-04       Impact factor: 2.882

8.  Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation.

Authors:  Masayoshi Yamamoto; Yoshihiro Seo; Naoto Kawamatsu; Kimi Sato; Akinori Sugano; Tomoko Machino-Ohtsuka; Ryo Kawamura; Hideki Nakajima; Miyako Igarashi; Yukio Sekiguchi; Tomoko Ishizu; Kazutaka Aonuma
Journal:  Circ Cardiovasc Imaging       Date:  2014-02-12       Impact factor: 7.792

9.  Estimation of left atrial blood stasis using diastolic late mitral annular velocity.

Authors:  Masaharu Masuda; Katsuomi Iwakura; Koichi Inoue; Atsunori Okamura; Yasushi Koyama; Yuko Toyoshima; Nobuaki Tanaka; Hiroyuki Nakanishi; Yohei Sotomi; Issei Komuro; Kenshi Fujii
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-11-08       Impact factor: 6.875

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  1 in total

1.  External validation and comparison of CHA2DS2-VASc-RAF and CHA2DS2-VASc-LAF scores for predicting left atrial thrombus and spontaneous echo contrast in patients with non-valvular atrial fibrillation.

Authors:  Nan Zheng; Jun Zhang
Journal:  J Interv Card Electrophysiol       Date:  2022-07-13       Impact factor: 1.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.